4D Molecular Therapeutics (NASDAQ:FDMT) Stock Rating Upgraded by Chardan Capital

4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by stock analysts at Chardan Capital to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

A number of other equities analysts have also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday, March 30th. The Goldman Sachs Group set a $33.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, May 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $29.88.

4D Molecular Therapeutics Stock Up 4.8%

4D Molecular Therapeutics stock opened at $10.07 on Tuesday. 4D Molecular Therapeutics has a twelve month low of $4.30 and a twelve month high of $14.00. The company has a market capitalization of $526.42 million, a P/E ratio of -3.92 and a beta of 2.70. The stock’s 50 day moving average is $10.55 and its 200 day moving average is $9.64.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The company had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. As a group, equities analysts expect that 4D Molecular Therapeutics will post -3.8 EPS for the current year.

Insider Activity

In other news, insider Scott Bizily sold 9,810 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the sale, the insider owned 8,617 shares of the company’s stock, valued at $103,404. This trade represents a 53.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the sale, the insider directly owned 942,485 shares of the company’s stock, valued at $9,867,817.95. The trade was a 10.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 184,811 shares of company stock worth $2,075,906 in the last 90 days. Company insiders own 7.90% of the company’s stock.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of FDMT. Dynamic Technology Lab Private Ltd purchased a new position in shares of 4D Molecular Therapeutics during the first quarter valued at about $39,000. Wexford Capital LP purchased a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth approximately $41,000. AQR Capital Management LLC purchased a new position in shares of 4D Molecular Therapeutics in the first quarter valued at $46,000. Daiwa Securities Group Inc. increased its position in 4D Molecular Therapeutics by 3,362.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after purchasing an additional 6,186 shares during the last quarter. Finally, Rangeley Capital LLC bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter worth about $48,000. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.